Does vunakizumab improve symptoms in patients with active axial spondyloarthritis?
Vunakizumab is a new anti-IL-17A monoclonal antibody being studied for axial spondyloarthritis (axSpA), specifically the radiographic form (r-axSpA, also called ankylosing spondylitis). A 2026 phase 2/3 clinical trial tested whether vunakizumab can reduce symptoms in people with active disease who have not responded well to other treatments. The short answer is yes: the trial found that vunakizumab led to significantly more patients achieving a 20% improvement in disease activity (ASAS20) at 16 weeks compared to placebo 57.
What the research says
The main evidence comes from a randomized, double-blind, placebo-controlled trial conducted in 38 hospitals in China, involving 548 adults with active r-axSpA 57. In phase 2, patients received either vunakizumab 120 mg, 240 mg, or placebo; after an interim analysis, 120 mg was chosen as the recommended dose. In phase 3, patients were randomized 2:1 to vunakizumab 120 mg or placebo at weeks 0, 2, 4, 8, and 12 57. The primary outcome was the proportion of patients achieving an ASAS20 response at week 16. The results showed that significantly more patients in the vunakizumab group reached this milestone compared to placebo 57. This means vunakizumab improved symptoms like pain, stiffness, and physical function in active disease. The trial also monitored safety, and while the abstract does not detail all adverse events, it notes that vunakizumab was generally well-tolerated 57. Importantly, this trial focused on radiographic axSpA (ankylosing spondylitis), not non-radiographic axSpA. The findings suggest vunakizumab is a promising new option for patients who have not had adequate response or could not tolerate existing therapies 57. Other sources in the set discuss broader topics like exercise therapy 2, malignancy risks with biologics 3, and perioperative DMARD management 4, but they do not directly address vunakizumab. One source reviews targeting metabolic checkpoints in axSpA but does not mention vunakizumab 1. Another meta-analysis covers genetic variants but not this drug 6. Therefore, the evidence for vunakizumab's symptom improvement is limited to this single trial, though it is a well-designed phase 2/3 study.
What to ask your doctor
- Is vunakizumab approved for use in my country, and is it available for axial spondyloarthritis?
- How does vunakizumab compare to other IL-17 inhibitors I might have tried, such as secukinumab or ixekizumab?
- What are the potential side effects of vunakizumab, especially since it is a new biologic?
- Would I be a candidate for vunakizumab based on my disease activity and previous treatments?
- Are there any ongoing trials or real-world data on vunakizumab's long-term safety and effectiveness?
This question is drawn from common patient questions about Rheumatology and answered using cited medical research. We do not provide individualized advice.